{"id":48802,"date":"2025-11-23T23:01:07","date_gmt":"2025-11-23T15:01:07","guid":{"rendered":"https:\/\/flcube.com\/?p=48802"},"modified":"2025-11-23T23:01:08","modified_gmt":"2025-11-23T15:01:08","slug":"sinovac-receives-nasdaq-delisting-notice-over-late-20-f-filing","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48802","title":{"rendered":"Sinovac Receives Nasdaq Delisting Notice Over Late 20-F Filing"},"content":{"rendered":"\n<p><strong>Sinovac Biotech Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/SVA:NASDAQ\">NASDAQ: SVA<\/a>) announced it received a <strong>delisting determination letter<\/strong> from Nasdaq for failing to comply with <strong>Listing Rule 5250(c)(1)<\/strong> by not filing its <strong>2024 Form 20-F annual report<\/strong> by the <strong>extension deadline of 11\u202fNov\u202f2025<\/strong>, following the resignation of auditor <strong>Grant Thornton<\/strong> in April. The company intends to request a hearing before the Nasdaq Hearing Panel to remain listed.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-delisting-notice-details\">Delisting Notice Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Sinovac Biotech Ltd. (Nasdaq: SVA)<\/td><\/tr><tr><td><strong>Notice Date<\/strong><\/td><td>12\u202fNov\u202f2025<\/td><\/tr><tr><td><strong>Delisting Rule<\/strong><\/td><td>Nasdaq Listing Rule 5250(c)(1) \u2013 Timely SEC filing requirement<\/td><\/tr><tr><td><strong>Violation<\/strong><\/td><td>Failure to file Form 20-F for year ended 31\u202fDec\u202f2024<\/td><\/tr><tr><td><strong>Extension Deadline<\/strong><\/td><td>11\u202fNov\u202f2025 (180\u2011day grace period expired)<\/td><\/tr><tr><td><strong>Potential Delisting<\/strong><\/td><td>21\u202fNov\u202f2025 (unless hearing requested and granted)<\/td><\/tr><tr><td><strong>Auditor Change<\/strong><\/td><td>Grant Thornton resigned 15\u202fApr\u202f2025; UHY LLP engaged as replacement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-compliance-timeline\">Compliance Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Date<\/th><th>Event<\/th><\/tr><\/thead><tbody><tr><td><strong>15\u202fApr\u202f2025<\/strong><\/td><td>Grant Thornton resigns as independent auditor<\/td><\/tr><tr><td><strong>30\u202fApr\u202f2025<\/strong><\/td><td>Original Form 20\u2011F filing deadline<\/td><\/tr><tr><td><strong>11\u202fNov\u202f2025<\/strong><\/td><td>Extension deadline to regain compliance (expired)<\/td><\/tr><tr><td><strong>12\u202fNov\u202f2025<\/strong><\/td><td>Nasdaq issues delisting determination letter<\/td><\/tr><tr><td><strong>21\u202fNov\u202f2025<\/strong><\/td><td>Suspension and delisting effective date (if no hearing)<\/td><\/tr><tr><td><strong>TBD<\/strong><\/td><td>Hearing request and 20\u2011F filing submission to Nasdaq<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-response\">Company Response<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hearing Request:<\/strong> Sinovac intends to <strong>timely request a hearing<\/strong> before the Nasdaq Hearing Panel to present its plan to regain compliance<\/li>\n\n\n\n<li><strong>New Auditor Engagement:<\/strong> <strong>UHY LLP<\/strong> has been engaged and is working diligently to complete the 2024 audit and file the Form 20\u2011F as soon as possible<\/li>\n\n\n\n<li><strong>Management Statement:<\/strong> Company emphasizes commitment to resolving the filing delay and maintaining Nasdaq listing<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Market Cap (Pre\u2011Notice)<\/strong><\/td><td>~$450\u202fmillion<\/td><\/tr><tr><td><strong>Share Price Impact<\/strong><\/td><td>Expected <strong>15\u201125% decline<\/strong> on delisting risk premium<\/td><\/tr><tr><td><strong>OTC Trading<\/strong><\/td><td>If delisted, shares would trade on OTC markets, reducing liquidity and institutional ownership<\/td><\/tr><tr><td><strong>Reputational Risk<\/strong><\/td><td>Auditor resignation and filing delay may raise corporate governance concerns among investors<\/td><\/tr><tr><td><strong>Recovery Timeline<\/strong><\/td><td>If 20\u2011F filed and hearing successful, relisting process could take <strong>3\u20116 months<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Investor Sentiment:<\/strong> The delisting notice adds to existing concerns about Sinovac\u2019s <strong>COVID\u201119 vaccine revenue sustainability<\/strong> and <strong>regulatory transparency<\/strong><\/li>\n\n\n\n<li><strong>Institutional Impact:<\/strong> Index funds (e.g., MSCI, FTSE) may be forced to sell if delisting proceeds, creating additional selling pressure<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Sinovac\u2019s ability to request a hearing, file its Form 20\u2011F, and maintain its Nasdaq listing. Actual outcomes may differ materially due to risks including auditor completion delays, Nasdaq panel decisions, and regulatory complications.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sinovac Biotech Ltd. (NASDAQ: SVA) announced it received a delisting determination letter from Nasdaq for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48803,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[1359,658],"class_list":["post-48802","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-nasdaq-sva","tag-sinovac-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sinovac Receives Nasdaq Delisting Notice Over Late 20-F Filing - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sinovac Biotech Ltd. (NASDAQ: SVA) announced it received a delisting determination letter from Nasdaq for failing to comply with Listing Rule 5250(c)(1) by not filing its 2024 Form 20-F annual report by the extension deadline of 11\u202fNov\u202f2025, following the resignation of auditor Grant Thornton in April. The company intends to request a hearing before the Nasdaq Hearing Panel to remain listed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48802\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sinovac Receives Nasdaq Delisting Notice Over Late 20-F Filing\" \/>\n<meta property=\"og:description\" content=\"Sinovac Biotech Ltd. (NASDAQ: SVA) announced it received a delisting determination letter from Nasdaq for failing to comply with Listing Rule 5250(c)(1) by not filing its 2024 Form 20-F annual report by the extension deadline of 11\u202fNov\u202f2025, following the resignation of auditor Grant Thornton in April. The company intends to request a hearing before the Nasdaq Hearing Panel to remain listed.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48802\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-23T15:01:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-23T15:01:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2301.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"601\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48802#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48802\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sinovac Receives Nasdaq Delisting Notice Over Late 20-F Filing\",\"datePublished\":\"2025-11-23T15:01:07+00:00\",\"dateModified\":\"2025-11-23T15:01:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48802\"},\"wordCount\":388,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48802#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2301.webp\",\"keywords\":[\"NASDAQ: SVA\",\"Sinovac Biotech\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48802#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48802\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48802\",\"name\":\"Sinovac Receives Nasdaq Delisting Notice Over Late 20-F Filing - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48802#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48802#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2301.webp\",\"datePublished\":\"2025-11-23T15:01:07+00:00\",\"dateModified\":\"2025-11-23T15:01:08+00:00\",\"description\":\"Sinovac Biotech Ltd. (NASDAQ: SVA) announced it received a delisting determination letter from Nasdaq for failing to comply with Listing Rule 5250(c)(1) by not filing its 2024 Form 20-F annual report by the extension deadline of 11\u202fNov\u202f2025, following the resignation of auditor Grant Thornton in April. The company intends to request a hearing before the Nasdaq Hearing Panel to remain listed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48802#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48802\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48802#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2301.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2301.webp\",\"width\":1080,\"height\":601,\"caption\":\"Sinovac Receives Nasdaq Delisting Notice Over Late 20-F Filing\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48802#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sinovac Receives Nasdaq Delisting Notice Over Late 20-F Filing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sinovac Receives Nasdaq Delisting Notice Over Late 20-F Filing - Insight, China&#039;s Pharmaceutical Industry","description":"Sinovac Biotech Ltd. (NASDAQ: SVA) announced it received a delisting determination letter from Nasdaq for failing to comply with Listing Rule 5250(c)(1) by not filing its 2024 Form 20-F annual report by the extension deadline of 11\u202fNov\u202f2025, following the resignation of auditor Grant Thornton in April. The company intends to request a hearing before the Nasdaq Hearing Panel to remain listed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48802","og_locale":"en_US","og_type":"article","og_title":"Sinovac Receives Nasdaq Delisting Notice Over Late 20-F Filing","og_description":"Sinovac Biotech Ltd. (NASDAQ: SVA) announced it received a delisting determination letter from Nasdaq for failing to comply with Listing Rule 5250(c)(1) by not filing its 2024 Form 20-F annual report by the extension deadline of 11\u202fNov\u202f2025, following the resignation of auditor Grant Thornton in April. The company intends to request a hearing before the Nasdaq Hearing Panel to remain listed.","og_url":"https:\/\/flcube.com\/?p=48802","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-23T15:01:07+00:00","article_modified_time":"2025-11-23T15:01:08+00:00","og_image":[{"width":1080,"height":601,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2301.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48802#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48802"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sinovac Receives Nasdaq Delisting Notice Over Late 20-F Filing","datePublished":"2025-11-23T15:01:07+00:00","dateModified":"2025-11-23T15:01:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48802"},"wordCount":388,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48802#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2301.webp","keywords":["NASDAQ: SVA","Sinovac Biotech"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48802#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48802","url":"https:\/\/flcube.com\/?p=48802","name":"Sinovac Receives Nasdaq Delisting Notice Over Late 20-F Filing - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48802#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48802#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2301.webp","datePublished":"2025-11-23T15:01:07+00:00","dateModified":"2025-11-23T15:01:08+00:00","description":"Sinovac Biotech Ltd. (NASDAQ: SVA) announced it received a delisting determination letter from Nasdaq for failing to comply with Listing Rule 5250(c)(1) by not filing its 2024 Form 20-F annual report by the extension deadline of 11\u202fNov\u202f2025, following the resignation of auditor Grant Thornton in April. The company intends to request a hearing before the Nasdaq Hearing Panel to remain listed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48802#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48802"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48802#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2301.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2301.webp","width":1080,"height":601,"caption":"Sinovac Receives Nasdaq Delisting Notice Over Late 20-F Filing"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48802#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sinovac Receives Nasdaq Delisting Notice Over Late 20-F Filing"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2301.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48802"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48802\/revisions"}],"predecessor-version":[{"id":48804,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48802\/revisions\/48804"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48803"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48802"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48802"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48802"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}